+Follow
ETLim Tiger
No personal profile
9
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
ETLim Tiger
09-22 10:46
News on Xtaipi
Movement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4246918544046012","uuid":"4246918544046012","gmtCreate":1783814520559,"gmtModify":1783815200129,"name":"ETLim Tiger","pinyin":"etlimtigeretlimtiger","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":9,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":610379906044192,"gmtCreate":1790045212509,"gmtModify":1790046789115,"author":{"id":"4246918544046012","authorId":"4246918544046012","name":"ETLim Tiger","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246918544046012","idStr":"4246918544046012"},"themes":[],"title":"","htmlText":"News on Xtaipi","listText":"News on Xtaipi","text":"News on Xtaipi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/610379906044192","repostId":"1183077960","repostType":2,"repost":{"id":"1183077960","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Market Focus","id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"pubTimestamp":1790043436,"share":"https://ttm.financial/m/news/1183077960?lang=en_US&edition=fundamental","pubTime":"2026-09-22 10:17","market":"us","language":"en","title":"Movement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1183077960","media":"Market Focus","summary":"On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior...","content":"<p><p>On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.</p><p>On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.</p><p>In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.</p><p>The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.</p><p>On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.</p><p>In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.</p><p>The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02228":"晶泰控股"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183077960","content_text":"On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","news_type":1,"symbols_score_info":{"02228":1}},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":610379906044192,"gmtCreate":1790045212509,"gmtModify":1790046789115,"author":{"id":"4246918544046012","authorId":"4246918544046012","name":"ETLim Tiger","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4246918544046012","idStr":"4246918544046012"},"themes":[],"title":"","htmlText":"News on Xtaipi","listText":"News on Xtaipi","text":"News on Xtaipi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/610379906044192","repostId":"1183077960","repostType":2,"repost":{"id":"1183077960","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Market Focus","id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"pubTimestamp":1790043436,"share":"https://ttm.financial/m/news/1183077960?lang=en_US&edition=fundamental","pubTime":"2026-09-22 10:17","market":"us","language":"en","title":"Movement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=1183077960","media":"Market Focus","summary":"On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior...","content":"<p><p>On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.</p><p>On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.</p><p>In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.</p><p>The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XTALPI Rises 5.59% in Regular Trading, Chairman Plans Up to HK$32 Million Share Purchase Amid Stanford Drug Discovery Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.</p><p>On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.</p><p>In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.</p><p>The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02228":"晶泰控股"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183077960","content_text":"On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","news_type":1,"symbols_score_info":{"02228":1}},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
